Last Updated : June 19, 2019
Details
Generic Name:
halobetasol propionate and tazarotene
Project Status:
Withdrawn
Therapeutic Area:
Psoriasis, moderate to severe plaque
Manufacturer:
Bausch Health, Canada Inc.
Brand Name:
TBC
Project Line:
Reimbursement Review
Project Number:
SR0600-000
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Topical treatment of moderate-to-severe plaque psoriasis.
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
Psoriasis, moderate to severe plaque
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Key Milestones2 | |
|---|---|
| Call for patient input posted | January 07, 2019 |
| Submission received | February 04, 2019 |
| Clarification: - Voluntarily withdrawn by the manufacturer on 2019-Feb-19 | |
Last Updated : June 19, 2019